Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway

Table 3

Effects of myricetin on echocardiographic parameters.

	CON	Myr	AB	AB+Myr
	10	10	10	10
HR (bpm)
IVSd (mm)				^#
LVEDd (mm)				^#
LVEPWd (mm)				^#
IVDs (mm)
LVEDs (mm)				^#
LVEPWs (mm)
EF (%)				^#
FS (%)				^#

HR: heart rate; IVSd: interventricular septal thickness (IVS) at diastole; IVSs: IVS at systole; LVEDd: LV end-diastolic diameter; LVEDs: LV end-systolic diameter; LVPWd: LV end-diastolic posterior wall thickness; LVPWs: LV end-systolic posterior wall thickness; LVEF: LV ejection fraction; FS: fractional shortening. versus the CON group or the Myr group, ^# versus the AB+Myr group.